Researchers identify genes involved in the development of malignant brain tumor

Uppsala University researchers have developed a new approach to identify functional mutations and their impact on genes applicable to the development of malignant brain tumor, glioblastoma, that is known to have a very poor prognosis. The study has been published in the Genome Biology journal.

Researchers identify genes involved in the development of malignant brain tumor
How to identify genes that can drive the development of brain tumors. Image Credit: Graphics: L. Gaffney.

The human genome contains virtually 22,000 genes. Several studies have investigated almost 2% of human DNA that creates proteins. Not much is known about the remaining 98% of DNA that fails to encode proteins.

But these non-coding regions do contain significant data and control whether a gene is active in different types of tissues, in different developmental stages, and in diseases like cancer.

Cancer is induced by mutations that result in the uncontrolled division of cells. Glioblastoma, a form of brain tumor known for its very poor prognosis, is one of the most aggressive forms of cancer. Researchers are not completely certain how mutations in non-coding regions cause glioblastoma.

Hence, to address this knowledge gap, Uppsala University researchers have carried out whole-genome sequencing of DNA in tumor tissues obtained from patients suffering from glioblastoma and examined the identified mutations.

One of our key tasks was to identify functional mutations associated with regulatory elements and potential relevance to the development of cancer cells, and to distinguish them from all random variations without presumed significance.”

Karin Forsberg Nilsson, Professor, Department of Immunology, Genetics, and Pathology, Uppsala University

The scientists assumed that DNA sequences that have continued to remain unchanged in mammals all through the evolution may probably have significant functions. Hence, the researchers intersected scores of mutations that were found to contain evolutionary conservation data of the genetic regions where the mutations exist.

We chose to focus on a subset of mutations in the best-preserved genetic regions that are likely to affect gene regulation.”

Kerstin-Lindblad-Toh, Professor, Department of Medical Biochemistry and Microbiology, Uppsala University

Professor Kerstin-Lindblad-Toh also works at the Broad Institute in the United States.

The scientists verified their results by employing a gene called SEMA3C, partially because they identified a huge number of mutations in non-coding regulatory regions close to this gene and partially because earlier findings, made by others, imply that the SEMA3C gene is associated with a poor cancer prognosis.

We studied how mutations in non-coding regions affect SEMA3C's function and activity. Our results show that a specific, evolutionarily conserved, mutation in the vicinity of SEMA3C disrupts the binding of certain proteins whose task is to bind genes and regulate their activity.”

Karin Forsberg Nilsson, Professor, Department of Immunology, Genetics, and Pathology, Uppsala University

This latest study also detected over 200 other genes enriched for non-coding mutations in the concerned regions. These genes may have regulatory potential that can further boost the number of genes involved in the development of brain tumors.

Our results confirm the importance of the association between genetic alterations in non-coding regions, their biological function and disease pathology,” Forsberg Nilsson concluded.

Journal reference:

Sakthikumar, S., et al. (2020) Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes. Genome Biology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unlocking Glucose-Driven Mechanisms of Immunosuppression in Glioblastoma